References
- Alshenawy HA (2010). Immunohistochemical expression of epidermal growth factor receptor, E-cadherin, and matrix metalloproteinase-9 in ovarian epithelialcancer and relation to patient deaths. Ann Diagn Pathol, 14, 387-95. https://doi.org/10.1016/j.anndiagpath.2010.05.005
- Aznavoorian S, Murphy AN, Stetler-Stevenson WG, et al (1993). Molecular aspects of tumor cell invasion and metastasis. Cancer, 71, 1368-83. https://doi.org/10.1002/1097-0142(19930215)71:4<1368::AID-CNCR2820710432>3.0.CO;2-L
- Berman ML (2003). Future directions in the surgical management of ovarian cancer. Gynecol Oncol, 90, S33-9. https://doi.org/10.1016/S0090-8258(03)00342-1
- Clark T, Stewart M, Altman D, et al (2001).A prognostic model for ovarian cancer. Br J Cancer, 85, 944. https://doi.org/10.1054/bjoc.2001.2030
- Davidson B, Goldberg I, Gotlieb WH, et al (1999). High levels of MMP-2, MMP-9, MT1-MMP and TIMP-2 mRNA correlate with poor survival in ovarian carcinoma. Clin Exp Metastasis, 17, 799-808. https://doi.org/10.1023/A:1006723011835
- Davidson B, Goldberg I, Kopolovic J, et al (1999). Expression of matrix metalloproteinase-9 in squamous cell carcinoma of the uterine cervix-clinicopathologic study using immunohistochemistry and mRNA in situ hybridization. Gynecol Oncol, 72, 380-6. https://doi.org/10.1006/gyno.1998.5285
-
Guo BQ, Yu L, Wu SW, et al (2011). Expression of HE4, NF-
${\kappa}b$ p65, MMP-9 and Their Clinical Significance in Epithelial Ovarian Noeplasm. Chinese J Histochem Cytochem, 20, 578-83. - Himelstein BP, Canete-Soler R, Berhnhard EJ, et al (1994-1995). Metalloproteinases in tumor progression: the contribution of MMP-9. Invas Metast, 14, 246-58.
- Huang LW, Garrett AP, Bell DA, et al (2000). Differential expression of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 protein and mRNA in epithelial ovarian tumors. Gynecol Oncol, 77, 369-76. https://doi.org/10.1006/gyno.2000.5806
- Hu J (2011). Expression of MMP2 and MMP9 in tissue of epithelial tumor of ovary and its clinical significance. Chin Med Mod Dis China, 9, 208-10.
- Hu XX, Li DR, Zhang W, et al (2012). Matrix metalloproteinase-9 expression correlates with prognosis and involved in ovarian cancer cell invasion. Arch Gynecol Obstet, 286, 1537-43. https://doi.org/10.1007/s00404-012-2456-6
- Jean LB, Cortez A, Lesieur B, et al (2012). Expression of MMP-2,-7,-9, MT1-MMP and TIMP-1 and -2 has no prognostic relevance in patients with advanced epithelial ovarian cancer. Oncol Rep, 27, 1049-57.
- Kamat AA, Fletcher M, Gruman LM, et al (2006).The clinical relevance of stromal matrix metalloproteinase expression in ovarian cancer. Clin Cancer Res, 12, 1707-14. https://doi.org/10.1158/1078-0432.CCR-05-2338
- Kessenbrock K, Plaks V, Werb Z (2010). Matrix metalloproteinases: regulators of the tumor microenvironment. Cell, 141, 52-67. https://doi.org/10.1016/j.cell.2010.03.015
- Lampert K, Machein U, Machein MR, et al (1998). Expression of matrix metalloproteinases and their inhibitors in human brain tumors. Am J Pathol, 153, 429-37. https://doi.org/10.1016/S0002-9440(10)65586-1
- Landis SH, Murray T, Bolden S, et al (1999). Cancer statistics. CA Cancer J Clin, 49, 8-31. https://doi.org/10.3322/canjclin.49.1.8
- Lengyel E, Schmalfeldt B, Konik E, et al (2001). Expression of latent matrix metalloproteinase 9 (MMP-9) predicts survival in advanced ovarian cancer. Gynecol Oncol, 82, 291C8.
- Li DC, Liang LZ, Deng GP (2008). The clinical significance of mmp-9 Protein expression in epithelial ovarian carcinoma. Prac J Cancer, 23, 001-2.
- Li JQ, Shi YF, Zhou HJ, et al (2003) . Express ions of MMP-9 and TIMP-1 in epithelial ovarian neoplasms. Prog Obstet Gynecol, 12, 1703.
- Lou G, Gao Y, Ning XM, et al (2005). Expression and correlation of CD44v6, vascular endothelial growth factor, matrix metalloproteinase-2, and matrix metalloproteinase-9 in Krukenberg tumor. World J Gastroenterol, 11, 5032-6.
- Maatta M, Santalaa M, Soini Y, et al (2004). Matrix metalloproteinases 2 and 9 and their tissue inhibitors in low malignant potential ovarian tumors. Tumor Biol, 25, 188-92. https://doi.org/10.1159/000081101
- Murray GI, Duncan ME, Arbuckle E, et al (1998). Matrix metalloproteinases and their inhibitors in gastric cancer. Gut, 43, 791-7. https://doi.org/10.1136/gut.43.6.791
- Naylor MS, Stamp GW, Davies BD, et al (1994). Expression and activity of MMPs and their regulators in ovarian cancer. Int J Cancer, 58, 50-6. https://doi.org/10.1002/ijc.2910580110
- Oldenhuis CN, Oosting SF, Gietema JA, et al (2008). Prognostic vs predictive value of biomarkers in oncology. Eur J Cancer, 44, 946-53. https://doi.org/10.1016/j.ejca.2008.03.006
- Ozalp S, Tanir HM, Yalcin OT, et al (2003). Prognostic value of matrix metalloproteinase (gelatinase-B) expression in epithelial ovarian tumors. Eur J Gynaec Oncol, 5, 417-20.
- Parmar MK, Torri V, Stewart L (1998). Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med, 17, 2815-34. https://doi.org/10.1002/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8
- Qin M, Hu YQ (2011). VEGF and MMP-9 in ovarian cancer tissues and lymph node invasion and metastasis of transfer correlation. China Med Pharm, 1, 20-1.
- Remacle AG, Noel A, Duggan C, et al (1998). Assay of matrix metalloproteinases types 1, 2, 3 and 9 in breast cancer. Br J Cancer, 77, 926-31. https://doi.org/10.1038/bjc.1998.153
- Shen YF, Xu LL, Li FS, et al (2006). Expression of MMP-9,VEGF,Ki-67 in Krukenberg tumor,epithelial ovarian neoplasm. J Nanjing Med U, 26, 873.
- Siegel R, Naishadham D, Jemal A (2012). Cancer statistics. CA Cancer J Clin, 62, 10-29. https://doi.org/10.3322/caac.20138
- Sillanpaa S, Anttila M, Voutilainen K, et al (2007). Prognostic significance of matrix metalloproteinase-9 (MMP-9) in epithelial ovarian cancer. Gynecol Oncol, 104, 296-303. https://doi.org/10.1016/j.ygyno.2006.09.004
- Sood AK, Fletcher MS, Coffin JE, et al (2004). Functional role of matrix metalloproteinases in ovarian tumor cell plasticity. Am J Obstet Gynecol, 190, 899-909. https://doi.org/10.1016/j.ajog.2004.02.011
- Stallings-Mann M, Radisky D (2007). Matrix metalloproteinase-induced malignancy in mammary epithelial cells. Cells Tissues Organs, 185, 104-10. https://doi.org/10.1159/000101310
- Steels E, Paesmans M, Berghmans T, et al (2001). Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis. Eur Respir J, 18, 705-19. https://doi.org/10.1183/09031936.01.00062201
- Sugiura Y, Shimada H, Seeger RC, et al (1998). Matrix metalloproteinases-2 and -9 are expressed in human neuroblastoma: contribution of stromal cells to their production and correlation with metastasis. Cancer Res, 58, 2209-16.
- Sun SE, Tian LL, Yu HL (2008). Value of MMP-9 and PCNA expression in epithelial ovarian tumor. Matern Child Health Care Chi, 23, 975-7.
- Tian LL, Zhen JH, Zhang LZ (2007). Expression and significance of MMP 9 in epithelial ovarian cancer. J Qiqihar Med Coll, 28, 788-9.
- Wang FL, Lou YH, Yang XS, et al (2011). Expression of EGFR and MMP-9 in epithelial ovarian cancer and their correlation with prognosis of patients. Prog ObstetGynecol, 20, 689-92.
- Wang XM, Sun L, Zhen RS, et al (2005). Expression and Clinical Significance of MMP -9 and TIMP -1 in Epithelial Ovarian Tumor Using Tissue Microarray Technique. Cancer Res on Pre and Treat, 32, 484-6.
- Wang XY,Zhang YK,Ren GC (2004). Relation between expression of MMP-2 and MMP-9 and invasion,metastasis of epithelial carcinoma of ovary. Chin J Clin Oncol Rehabil, 11, 406-8.
- Wu JX, Zhao Y, Jia SJ, et al (2007). Expressions of MMP-2, MMP-3, MMP-9 and CD147 in human ovarian cancer and their clinicopathological s ignificance. J Chongqing Med U, 32, 1165-8.
- Xing LY , Cai DG, Fang XH, et al (2007). Study of expression and correlation of cathepsin B and matrix metallo-proteinase-9 in epithelial ovarian tumor. J Xi'an Jiaotong U, 28, 582-4.
- Yan H, Tan WH (2008). Expression of VEGF and MMP-9 in the epithelial ovavian cavcinoma and its significance. Hei Long Jiang Med J, 32, 89-92.
- Yusuf S, Peto R, Lewis J, et al (1985). Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis, 27, 335-71. https://doi.org/10.1016/S0033-0620(85)80003-7
- Zeng XL, Peng YJ (2010). Expression and clinical significance of VEGF, MMP-2 and MMP-9 invovarian carcinoma. Prog Mod Bio, 10, 2322-4.
- Zeng ZS, Cohen AM, Guillem JG (1999). Loss of basement membrane type IV collagen is associated with increased expression of metalloproteinase 2 and 9 (MMP-2 ad MMP-9) during human colorectal tumorigenesis. Carcinogenesis, 20, 749-55. https://doi.org/10.1093/carcin/20.5.749
- Zhang DN, Zhang QH, Li HM (2011). Expression and significance of MMP 9 and VEGF in ovarian cancer. Chin J Lab Diagn, 15, 1384-95.
- Zhang HJ, Wu XH, Ruo R (2006). Study on the expressions of vascular endothelial growth factor and its receptors and matrix metalloproteinase 9 in epithelial ovarian cancer. Tianjin Med J, 34, 165-7.
- Zhang LJ,Tan WH,Yang QH (2007). Expression and significance of MMP 9 and laminin receptor in epithelial ovarian neoplasm. Chin J Birth Health Hered, 15, 31-2.
Cited by
- Expression of High Mobility Group Box - B1 (HMGB-1) and Matrix Metalloproteinase-9 (MMP-9) in Non-small Cell Lung Cancer (NSCLC) vol.15, pp.12, 2014, https://doi.org/10.7314/APJCP.2014.15.12.4865
- Impact of Prognostic Factors on Survival Rates in Patients with Ovarian Carcinoma vol.15, pp.15, 2014, https://doi.org/10.7314/APJCP.2014.15.15.6087
- Cinobufacin Suppresses Cell Proliferation via miR-494 in BGC-823 Gastric Cancer Cells vol.15, pp.3, 2014, https://doi.org/10.7314/APJCP.2014.15.3.1241
- Decreased expression of carbonyl reductase 1 promotes ovarian cancer growth and proliferation vol.46, pp.3, 2015, https://doi.org/10.3892/ijo.2014.2810
- Inhibition of Metastasis and Invasion of Ovarian Cancer Cells by Crude Polysaccharides from Rosa Roxburghii Tratt in Vitro vol.15, pp.23, 2015, https://doi.org/10.7314/APJCP.2014.15.23.10351
- Ovarian cancer: involvement of the matrix metalloproteinases vol.150, pp.2, 2015, https://doi.org/10.1530/REP-14-0546
- MMP2 Gene-735 C/T and MMP9 gene -1562 C/T Polymorphisms in JAK2V617F Positive Myeloproliferative Disorders vol.16, pp.2, 2015, https://doi.org/10.7314/APJCP.2015.16.2.443
- Microvessel Density as a Prognostic Factor in Ovarian Cancer: a Systematic Review and Meta-analysis vol.16, pp.3, 2015, https://doi.org/10.7314/APJCP.2015.16.3.869
- Nitidine chloride inhibits ovarian cancer cell migration and invasion by suppressing MMP-2/9 production via the ERK signaling pathway vol.13, pp.4, 2016, https://doi.org/10.3892/mmr.2016.4929
- Relationship between matrix metalloproteinases and the occurrence and development of ovarian cancer vol.50, pp.6, 2017, https://doi.org/10.1590/1414-431x20176104
- Matrix Metalloproteinase-9 (MMP-9) as a Cancer Biomarker and MMP-9 Biosensors: Recent Advances vol.18, pp.10, 2018, https://doi.org/10.3390/s18103249